Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EPS (Basic) (2016 - 2025)

CorMedix has reported EPS (Basic) over the past 16 years, most recently at $0.13 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.13 for Q4 2025, down 45.83% from a year ago — trailing twelve months through Dec 2025 was $2.16 (up 796.77% YoY), and the annual figure for FY2025 was $2.25, up 850.0%.
  • EPS (Basic) reached $0.13 in Q4 2025 per CRMD's latest filing, down from $1.42 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.42 in Q3 2025 and bottomed at -$0.26 in Q4 2023.
  • Median EPS (Basic) over the past 5 years was -$0.18 (2022), compared with a mean of -$0.03.
  • The largest annual shift saw EPS (Basic) plummeted 58.33% in 2022 before it soared 2940.0% in 2025.
  • Over 5 years, EPS (Basic) stood at -$0.21 in 2021, then grew by 4.76% to -$0.2 in 2022, then plummeted by 30.0% to -$0.26 in 2023, then skyrocketed by 192.31% to $0.24 in 2024, then crashed by 45.83% to $0.13 in 2025.
  • Business Quant data shows EPS (Basic) for CRMD at $0.13 in Q4 2025, $1.42 in Q3 2025, and $0.29 in Q2 2025.